Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008

Manufacturer: Elevar Therapeutics
Regulatory submission: NDA submitted January 2026
Launch: Anticipated in the fourth quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Product description

Product information

100 evidence topics · 33 sources

Generic, brand name and therapeutic class of product6 evidence topics · 7 sources
Dosage forms and strengths4 evidence topics · 2 sources
Average sales price and wholesale acquisition cost2 evidence topics · 3 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 2 sources
Indication4 evidence topics · 3 sources
Pharmacology19 evidence topics · 6 sources
Contraindications/Warnings/Precautions/Adverse effects12 evidence topics · 5 sources
Special populations7 evidence topics · 2 sources
Drug/Drug, drug/disease interactions7 evidence topics · 3 sources
Dosing and administration9 evidence topics · 2 sources
Access and distribution3 evidence topics · 6 sources
Co-prescribed/Concomitant therapies6 evidence topics · 2 sources
Product comparison19 evidence topics · 19 sources

Effect of Lirafugratinib on quality measures

Product-specific effect on quality measures

No evidence found.